v3.26.1
SCHEDULE OF SELECTED INFORMATION FOR REPORTABLE SEGMENTS (Details) - USD ($)
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Operating income by Segment $ 69,281,380 $ 32,121,818
Abbreviated New Drug Applications [Member]    
Segment Reporting [Line Items]    
Operating income by Segment $ 69,281,380 $ 32,121,818